Biodexa Pharmaceuticals (BDRX) announced it has selected Serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis In conjunction with this announcement, the company launched a dedicated website, www.serentatrial.com, to provide information and resources for patients, caregivers, and healthcare professionals. Serenta reflects Biodexa’s commitment to supporting the FAP community and fostering collaboration with stakeholders. The new website offers details about the study’s objectives, background on FAP, and ongoing updates as the program progresses.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Announces Successful Passing of General Meeting Resolutions
- Biodexa Pharmaceuticals Initiates Phase 2 Study for Type 1 Diabetes Treatment
- Biodexa announces recruitment of first patient in Phase 2 tolimidone study
- Biodexa Pharmaceuticals Provides Shareholder Update and Advances eRapa Phase 3 Program
- Biodexa Pharmaceuticals sees cash runway into 1Q26